/PRNewswire/ Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic therapies for treatment of retinal degenerative.
Convocatoria de ayudas a la investigación de ONCE para la visión discapnet.es - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from discapnet.es Daily Mail and Mail on Sunday newspapers.
LumiThera présente les bénéfices du traitement par photobiomodulation utilisant le système Valeda chez les patients atteints de rétinopathie diabétique précoce avec œdème maculaire prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Intellia Therapeutics, Inc. (NASDAQ: NTLA) (before the market open)
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) (before the market open)
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) (before the market open)
Insmed Incorporated (NASDAQ: INSM) (before the market open)
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) (before the market open)
Endo International plc (NASDAQ: ENDP) (before the market open)
Bio-Techne Corporation (NASDAQ: TECH) (before the market open)
Harvard Bioscience, Inc. (NASDAQ: HBIO) (before the market open)
Athenex, Inc. (NASDAQ: ATNX) (before the market open)
Zoetis Inc. (NYSE: ZTS) (before the market open)
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (before the market open)
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) (before the market open)
iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABBV) - The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.